Medicare Prescription Drug Savings and Choice Act of 2019

To amend part D of title XVIII of the Social Security Act to deliver a meaningful benefit and lower prescription drug prices under the Medicare program. 1. Short title This Act may be cited as the Medicare Prescription Drug Savings and Choice Act of 2019 2. Establishment of Medicare operated prescription drug plan option (a) In general Subpart 2 of part D of title XVIII of the Social Security Act is amended by inserting after section 1860D–11 ( 42 U.S.C. 1395w–111 1860D–11A. Medicare operated prescription drug plan option (a) In general Notwithstanding any other provision of this part, for each year (beginning with 2021), in addition to any plans offered under section 1860D–11, the Secretary shall offer one or more Medicare operated prescription drug plans (as defined in subsection (d)) with a service area that consists of the entire United States and shall enter into negotiations in accordance with subsection (c) with pharmaceutical manufacturers to reduce the purchase cost of covered part D drugs for eligible part D individuals who enroll in such a plan. (b) Enrollment Notwithstanding subparagraphs (C) and (D) of section 1860D–1(b)(1), a Medicare operated prescription drug plan offered under this section shall serve as the default prescription drug plan for all part D enrollees unless another prescription drug plan is selected. (c) Negotiations Notwithstanding section 1860D–11(i), for purposes of offering a Medicare operated prescription drug plan under this section, the Secretary shall negotiate with pharmaceutical manufacturers with respect to the purchase price of covered part D drugs in a Medicare operated prescription drug plan and shall encourage the use of more affordable therapeutic equivalents to the extent such practices do not override medical necessity as determined by the prescribing physician. To the extent practicable and consistent with the previous sentence, the Secretary shall implement negotiation and incentive strategies similar to those used by other Federal purchasers of prescription drugs to reduce the purchase cost of covered Part D drugs, and other strategies, as described in subsection (f), which may include the use of a pricing scale based on an international price index. (d) Medicare operated prescription drug plan defined For purposes of this part, the term Medicare operated prescription drug plan (e) Monthly beneficiary premium (1) Qualified prescription drug coverage The monthly beneficiary premium for qualified prescription drug coverage and access to negotiated prices described in section 1860D–2(a)(1)(A) to be charged under a Medicare operated prescription drug plan shall be uniform nationally. Such premium for months in 2021 and each succeeding year shall be based on the average monthly per capita actuarial cost of offering the Medicare operated prescription drug plan for the year involved, including administrative expenses. (2) Supplemental prescription drug coverage Insofar as a Medicare operated prescription drug plan offers supplemental prescription drug coverage, the Secretary may adjust the amount of the premium charged under paragraph (1). (f) Use of negotiation and benefit design incentives (1) In general With respect to the operation of a Medicare operated prescription drug plan and in negotiating with respect to the purchase price of covered part D drugs in such plan, the Secretary shall reward value, increase appropriate use of drugs, and ensure patient safety and access to medications. (2) Role of AHRQ The Director of the Agency for Healthcare Research and Quality, in coordination with the Administrator of the Centers for Medicare & Medicaid Services, shall be responsible for assessing the clinical benefit of covered part D drugs and making recommendations to the Secretary regarding the negotiated prices of covered drugs and any appropriate tiering or incentive strategies under the plan. In conducting such assessments and making such recommendations, the Director shall carry out the following activities: (A) Consider the comparable international price of such drugs based upon the median retail list price of such drug (which shall be, as practicable, the volume-weighted price for comparable units and dosage forms) among a category of at least the following peer reference countries: Canada, the United Kingdom, France, Japan, Australia, and Germany. (B) Consider safety concerns and post-market data, including those identified by the Food and Drug Administration and from national health registries. (C) Use available data and evaluations, including from research supported by the National Institutes of Health, with priority given to randomized controlled trials, to examine clinical effectiveness, comparative effectiveness, safety, and enhanced compliance with a drug regimen. (D) Use the same classes of drugs developed by United States Pharmacopeia for this part. (E) Consider evaluations made by— (i) the Director under section 1013 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003; (ii) other Federal entities, such as the Secretary of Veterans Affairs; and (iii) other private and public entities, which may include the Drug Effectiveness Review Project and Medicaid programs. (F) Consider recommendations made by the advisory committee pursuant to paragraph (3)(F). (G) Recommend to the Secretary those drugs in a class that provide a greater clinical benefit, including fewer safety concerns or less risk of side-effects, than another drug in the same class. (3) Use of advisory committee (A) In general The Secretary shall establish and appoint an advisory committee (in this paragraph referred to as the advisory committee (i) to review petitions from drug manufacturers, health care provider organizations, patient groups, and other entities regarding negotiated prices; and (ii) to recommend any changes in order to further negotiations with respect to such prices. (B) Composition Subject to subparagraph (C), the advisory committee shall be composed of 9 members and shall include representatives of physicians, pharmacists, consumers, and others with expertise in evaluating prescription drugs. The Secretary shall select members based on their knowledge of pharmaceuticals and the Medicare population. Members shall be deemed to be special Government employees for purposes of applying the conflict of interest provisions under section 208 of title 18, United States Code, and no waiver of such provisions for such a member shall be permitted. (C) Banned individuals (i) Drug company lobbyists No former registered drug manufacturer lobbyist— (I) may be appointed to the advisory committee; or (II) may be employed by the advisory committee during the 6-year period beginning on the date on which the registered lobbyist terminates its registration in accordance with section 4(d) of the Lobbying Disclosure Act of 1995 ( 2 U.S.C. 1603(d) (ii) Senior executives of law-breaking companies No former senior executive of a covered entity (as defined in clause (iii))— (I) may be appointed to the Advisory Committee; or (II) may be employed by the Advisory Committee during the 6-year period beginning on the later of— (aa) the date of the settlement described in item (aa) of clause (iii)(II); or (bb) the date on which the enforcement action described in item (bb) of such clause has concluded. (iii) Covered entity The term covered entity (I) a drug manufacturer; and (II) (aa) operating under Federal settlement including a Federal consent decree; or (bb) the subject of an enforcement action in a court of the United States or by an agency. (D) Consultation The advisory committee shall consult, as necessary, with physicians who are specialists in treating the disease for which a drug is being considered. (E) Request for studies The advisory committee may request the Agency for Healthcare Research and Quality or an academic or research institution to study and make a report on a petition described in subparagraph (A)(i) in order to assess cost-effectiveness, clinical effectiveness, comparative effectiveness, safety, and compliance with a drug regimen. (F) Recommendations The advisory committee shall make recommendations to the Director of the Agency for Healthcare Research and Quality regarding the appropriate price at which to begin negotiations on a part D drug pursuant to this section. (G) Limitations on review of manufacturer petitions The advisory committee shall not review a petition of a drug manufacturer under subparagraph (A)(i) with respect to a covered part D drug unless the petition is accompanied by the following: (i) Raw data from clinical trials on the safety and effectiveness of the drug. (ii) Any data from clinical trials conducted using active controls on the drug or drugs that are the current standard of care. (iii) Any available data on comparative effectiveness of the drug. (iv) Any other information the Secretary requires for the advisory committee to complete its review. (g) Informing beneficiaries The Secretary shall take steps to inform part D eligible individuals not previously enrolled in a Medicare operated drug plan (including such individuals who are newly eligible to enroll under this part) regarding the enrollment of such individual in a Medicare operated drug plan in accordance with this section, including providing information in the annual handbook and adding information to the official public Medicare website related to prescription drug coverage available through this part. (h) Application of all other requirements for prescription drug plans Except as specifically provided in this section, any Medicare operated drug plan shall meet the same requirements as apply to any other prescription drug plan, including the requirements of section 1860D–4(b)(1) relating to assuring pharmacy access. . (b) Conforming amendments (1) Section 1860D–3(a) of the Social Security Act 42 U.S.C. 1395w–103(a) (4) Availability of the medicare operated prescription drug plan A Medicare operated prescription drug plan (as defined in section 1860D–11A(d)) shall be offered nationally in accordance with section 1860D–11A. . (2) (A) Section 1860D–3 of the Social Security Act ( 42 U.S.C. 1395w–103 (c) Provisions only applicable in 2006 through 2020 The provisions of this section shall only apply with respect to 2006 through 2020. . (B) Section 1860D–11(g) of such Act ( 42 U.S.C. 1395w–111(g) (8) No authority for fallback plans after 2020 A fallback prescription drug plan shall not be available after December 31, 2020. . (3) Section 1860D–13(c)(3) of the Social Security Act ( 42 U.S.C. 1395w–113(c)(3) (A) in the heading, by inserting and Medicare operated prescription drug plans Fallback plans (B) by inserting or a Medicare operated prescription drug plan a fallback prescription drug plan (4) Section 1860D–16(b)(1) of the Social Security Act ( 42 U.S.C. 1395w–116(b)(1) (A) in subparagraph (C), by striking and (B) in subparagraph (D), by striking the period at the end and inserting ; and (C) by adding at the end the following new subparagraph: (E) payments for expenses incurred with respect to the operation of Medicare operated prescription drug plans under section 1860D–11A. . (5) Section 1860D–41(a) of the Social Security Act ( 42 U.S.C. 1395w–151(a) (19) Medicare operated prescription drug plan The term Medicare operated prescription drug plan . (c) Rule of construction Nothing in this section shall be interpreted to supersede any other negotiation authority granted to the Secretary under Federal law with respect to prescription drug prices. 3. Improved appeals process under the Medicare operated prescription drug plan Section 1860D–4(h) of the Social Security Act ( 42 U.S.C. 1305w–104(h) (4) Appeals process for Medicare operated prescription drug plan (A) In general The Secretary shall develop a well-defined process for appeals for denials of benefits under this part under the Medicare operated prescription drug plan (as defined in section 1860D–11A(d)). Such process shall be efficient, impose minimal administrative burdens, and ensure the timely procurement of medications. Medical necessity shall be based on professional medical judgment, the medical condition of the beneficiary, and other medical evidence. (B) Consultation in development of process In developing the appeals process under subparagraph (A), the Secretary shall consult with consumer and patient groups, as well as other key stakeholders, to ensure the goals described in subparagraph (A) are achieved. .

Summary: Medicare Prescription Drug Savings and Choice Act of 2019 This bill requires the Centers for Medicare &amp; Medicaid Services (CMS) to establish at least one prescription drug plan that is operated by Medicare. Among other things, the plan must (1) serve the entire United States; and (2) be the default plan for enrollees under the Medicare prescription drug benefit, unless the enrollee chooses another plan. Additionally, the CMS must negotiate prices for prescription drugs that are covered under the plan and, if appropriate, encourage the use of more affordable therapeutic equivalents. (Currently, the CMS is prohibited from negotiating the prices of covered drugs under the Medicare prescription drug benefit.) The Agency for Healthcare Research and Quality must assess the clinical benefits of drugs and make recommendations to the CMS regarding price negotiations, based on specified information (e.g., comparable international prices).